GlassScriptPhysician profile
Victor L Cheang
NPI 1528240926
$18,988.67
in general payments reported to CMS, 2019-2025
16 companies · $3,762 in 2025
The $3,762 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,690 · 2020: $947 · 2021: $1,370 · 2022: $2,811 · 2023: $3,251 · 2024: $3,157 · 2025: $3,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,143.22 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,518.50 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $3,056.47 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,054.31 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,878.42 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,404.88 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,389.81 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $1,066.78 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $536.78 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $263.00 | 2022-2025 | Vraylar |
| Lundbeck LLC | $252.45 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $243.33 | 2019 | |
| Allergan, INC. | $142.26 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $120.52 | 2023 | Quviviq |
| Indivior INC. | $26.32 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $22.87 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Cheang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.